Gene

CDK6

cyclin dependent kinase 6

Explore in graph →CI-GENE-00040746HGNC:1777 ENSG00000105810 NCBI 1021 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (8)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDK6 Amplification2
Abemaciclib	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	D	Does Not Support Resistance	4	submitted	EID4843 Inhibitors of CDK4/6 complex have advanced in clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). Consecutively resistance to these agents has… (full text at CIViC) PMID 27748766 · Yang et al., 2017 · Open in CIViC	civic
Palbociclib	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID12398 Preclinical experiments using patient-derived GBM cell lines were performed to examine efficacy of CDK4/6 inhibitor palbociclib. The cell line CCF-STTG1 that harbours CDK6 amplification was sensitive … (full text at CIViC)

Cohorts

Alteration frequency by cohort (16)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved16 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm	8

Literature

Linked publications (3)

25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
· Clin Cancer Res · 2016 · PMID 27252418 · validated civic_curation pubmed
Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
· Biochem Pharmacol · 2018 · PMID 29408328 · validated civic_curation pubmed
CDK4/6 inhibition is more active against the glioblastoma proneural subtype.
· Oncotarget · 2017 · PMID 28903422 · validated civic_curation pubmed

CDK6 EXPRESSION1
Dexamethasone + RibociclibCombination	Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED	Predictive	D	Supports Sensitivity Response	2	accepted	EID7801 CDK6 was found to be significantly overexpressed in the bone marrow of B-ALL patients (n=299) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) a… (full text at CIViC) PMID 29408328 · Bortolozzi et al., 2018 · Open in CIViC	civic

CDK6 EXPRESSION1

Dexamethasone + RibociclibCombination

Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID7801

CDK6 was found to be significantly overexpressed in the bone marrow of B-ALL patients (n=299) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) a… (full text at CIViC)

PMID 29408328 · Bortolozzi et al., 2018 · Open in CIViC

civic

CDK6 Overexpression5
Fulvestrant	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	B	Supports Resistance	4	accepted	EID1526 In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months an… (full text at CIViC) PMID 27252418 · Alves et al., 2016 · Open in CIViC	civic
Fulvestrant + PalbociclibCombination	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	D	Supports Sensitivity Response	2	accepted	EID1527 Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity … (full text at CIViC) PMID 27252418 · Alves et al., 2016 · Open in CIViC	civic
Palbociclib	Malignant Breast Neoplasm	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11200 The PALOMA-3 trial compared palbociclib plus fulvestrant vs placebo plus fulvestrant and evaluated molecular correlates of response in 302 patients with metastatic breast cancer. mRNA expression level… (full text at CIViC) PMID 30807234 · Turner et al., 2019 · Open in CIViC	civic
〃	Glioblastoma Proneural SubtypeUNRESOLVED	Predictive	D	Supports Sensitivity Response	2	accepted	EID7800 In this study twelve GBM cell lines and normal human astrocytes (NHA) were treated with the CDK4/6 inhibitor palbociclib. NHA and several GBM cell lines were resistant to palbociclib with IC50 values … (full text at CIViC) PMID 28903422 · Li et al., 2017 · Open in CIViC	civic
Dexamethasone + RibociclibCombination	Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED	Predictive	D	Supports Sensitivity Response	3	rejected	EID8113 CDK6 was found to be significantly overexpressed in the bone marrow of B-ALL patients (n=299) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) a… (full text at CIViC) PMID 29408328 · Bortolozzi et al., 2018 · Open in CIViC	civic

CDK6 Overexpression5

Fulvestrant

Estrogen Receptor-positive Breast CancerUNRESOLVED

Predictive

Supports Resistance

accepted

EID1526

In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months an… (full text at CIViC)

PMID 27252418 · Alves et al., 2016 · Open in CIViC

civic

Fulvestrant + PalbociclibCombination

Estrogen Receptor-positive Breast CancerUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID1527

Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity … (full text at CIViC)

PMID 27252418 · Alves et al., 2016 · Open in CIViC

civic

Palbociclib

Malignant Breast Neoplasm

Predictive

Does Not Support Sensitivity Response

submitted

EID11200

The PALOMA-3 trial compared palbociclib plus fulvestrant vs placebo plus fulvestrant and evaluated molecular correlates of response in 302 patients with metastatic breast cancer. mRNA expression level… (full text at CIViC)

PMID 30807234 · Turner et al., 2019 · Open in CIViC

civic

〃

Glioblastoma Proneural SubtypeUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID7800

In this study twelve GBM cell lines and normal human astrocytes (NHA) were treated with the CDK4/6 inhibitor palbociclib. NHA and several GBM cell lines were resistant to palbociclib with IC50 values … (full text at CIViC)

PMID 28903422 · Li et al., 2017 · Open in CIViC

civic

Dexamethasone + RibociclibCombination

Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED

Predictive

Supports Sensitivity Response

rejected

EID8113

PMID 29408328 · Bortolozzi et al., 2018 · Open in CIViC

civic